T1	Participants 111 133	breast cancer patients
T2	Participants 195 232	postmenopausal breast cancer patients
T3	Participants 384 407	breast cancer survivors
T4	Participants 831 886	postmenopausal patients with a history of breast cancer
T5	Participants 909 944	Seventy-one postmenopausal patients
T6	Participants 1434 1493	patients receiving MPA or megestrol, respectively (P = 0.5)
T7	Participants 972 1081	an i.m. injection of depot MPA 500 mg on days 1, 14 and 28, or oral megestrol acetate 40 mg daily for 6 weeks
T8	Participants 1644 1661	89% of responders
T9	Participants 1711 1748	45% in the megestrol group (P = 0.03)
T11	Participants 1906 1947	patients with a history of breast cancer,
